Primum non nocere (first, not to harm) and secundus, opinio vulnero (second, report the harm)
- PMID: 19946404
- PMCID: PMC2777278
- DOI: 10.1155/2009/303509
Primum non nocere (first, not to harm) and secundus, opinio vulnero (second, report the harm)
References
-
- Tercica, Inc. INCRELEXTM (mecasermin [rDNA origin] injection), Tercica, Brisbane, Calif, USA, August 2005.
-
- Tao Y, Pinzi V, Bourhis J, Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer. Nature Clinical Practice Oncology. 2007;4(10):591–602. - PubMed
-
- Rosenbloom AL. The role of recombinant insulin-like growth factor I in the treatment of the short child. Current Opinion in Pediatrics. 2007;19(4):458–464. - PubMed
-
- Strom BL, Melmon KL, Miettinen OS. Post-marketing studies of drug efficacy: why? The American Journal of Medicine. 1985;78(3):475–480. - PubMed
-
- Torjusen E, Calderon J, Rivkees SA. Anaphylactic reaction to recombinant insulin-like growth factor-I. Journal of Pediatric Endocrinology & Metabolism. 2008;21(4):381–384. - PubMed
LinkOut - more resources
Full Text Sources
